XLRN News and Press, Acceleron Pharma Inc. From 06/24/20

Acceleron Pharma ( XLRN -5.5% ) announces positive results from a Phase 2 clinical trial, PULSAR , evaluating sotatercept in pulmonary arterial hypertension (PAH) patients. The data were presented virtually at the American Thoracic Society Conference. More news on: Acceleron Pharma In...

- Data presented during ‘Breaking News’ Session of the American Thoracic Society 2020 Virtual Conference (ATS 2020 Virtual) show the PULSAR trial achieved its primary endpoint: a statistically significant mean reduction in pulmonary vascular resistance (PVR) - - Patients ...

Thanks to exchange-traded funds (ETFs), investors don’t have to be tied to one specific stock. Biotech ETFs allow market participants to invest in multiple biotech companies via one vehicle. The life science sector certainly holds a risk factor, and ETFs are a good way to enter th...

Acceleron Pharma ( XLRN +0.9% ) will host a conference call on Wednesday, June 24, at 4:30 pm ET to discuss topline results from a Phase 2 clinical trial, PULSAR , evaluating sotatercept in patients with pulmonary arterial hypertension (PAH). The data will have been presented virtually ...

Acceleron Pharma Inc. (Nasdaq: XLRN), a leading biopharmaceutical company in the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced it will host a conference call and webcast on Wednesday, June 24, 2020 at 4:3...

Market Pulse The question of whether it's a new bull market rally or just an intermittent bear market rally doomed to end later this year will most likely be decided late in the third quarter or during the fourth quarter when enough evidence on the durability of the recovery pace is forthcom...

Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, announced today the appointment of Christopher Hite to its Board of Directors. Mr. Hite is...

Acceleron Pharma Inc. (Nasdaq: XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that a total of six distinct abstracts on REBLOZYL ® (luspatercept-...

Acceleron to host an investor and analyst webcast and conference call following the virtual ATS 2020 presentation on June 24 th Acceleron Pharma Inc. (Nasdaq: XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily the...

Preclinical research of murine version of sotatercept reveals significant role of key TGF-beta superfamily proteins, including activin and growth differentiation factor ligands, in pulmonary vascular disease; points to therapeutic strategy in pulmonary arterial hypertension (PAH) Accel...